The effect of lithium carbonate on leukopenia after chemotherapy

To evaluate the efficacy of lithium carbonate in ameliorating leukopenia, 37 patients (3 to 26 years old, mea (less than or equal to 1,000/mm3) over 40% of the time were designated at random on the last day of 82 separate chemotherapy courses to receive lithium or no treatment. Four could not take the drug because of the size of the capsules. There were 39 controls and 39 patients given lithium. Blood levels were maintained at 0.2 to 1.2 mEq/1 (median 0.7). The median drop of WBC in the treated group was 3,400/mm3 with a nadir of 1,800/mm3 vs 5,000 and 1,400, respectively, for the untreated patients (P LESS THAN 0.01). Eight patients (21%) in the lithium-treated group became severly leukopenic (less than or equal to 1,000/mm3) while 14 (36%) in the control group became leukopenic to that extent. Twenty-four patient days were spent with the WBC less than or equal to 1,000/mm3 after lithium and 57 days in the control group. Three patients required admission for 24 hospital days for fever while leukopenic after lithium, whereas seven patients spent 62 days in the hospital in the control group. Lithium reduces the period of leukopenia after chemotherapy during which time the patients may acquire infections.

Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease

Serum levels of circulating immune complexes (CIC) assayed by the Raji cell radioimmunoassay, total haemolytic complement (TCH50), Clq and C3 were correlated with clinical stage, histological type, age, sex and treatment of eighty-six children with Hodgkin's disease over a period of 4 years. Most significant findings were the changes of levels of CIC, TCH50, Clq and C3 during disease activity and following treatment. Significant perturbations were also seen in association with relapse. Levels of C and CIC were significantly elevated (P less than 0.001) at the time of diagnosis prior to splenectomy and/or any treatment. In the group before treatment, 81 percent of CIC levels were above 16 micrograms/ml with a maximum value of 1120 micrograms/ml. During treatment 33 percent were still above normal with a maximum of 320 micrograms/ml. Within 1 year after cessation of treatment, 37 percent also remained above normal levels with a maximum of 240 micrograms/ml. At relapse prior to treatment, 63 percent were again elevated with a maximum of 1280 micrograms/ml. The most significant difference on TCH50 levels relates to treatment periods. Sera of patients with active disease who are previously untreated show elevation of TCH50 levels (P less than 0.001) (average 127 CH50 mu/ml. During and after treatment eht TCH50 levels drop to 96 and 102 CH50 mu/ml, as compared to normal control of 100 CH50 mu/ml. In sera of patients at the first, second or third relapse, the combined TCH50 levels are significantly different from controls and across treatment periods (P less than 0.005).

A new method of treatment of congenital tibial pseudoarthrosis using free vascularised fibular graft: a preliminary report

This paper reports our experience of using Vascularised Fibular Transfer in Treatment of Congenital Pseudoarthrosis of tibia in 12 cases. Although the preliminary results of bony union are encouraging, the long term results can only be assessed after skeletal maturity.

Circulating immune complexes in sera of children with neuroblastoma: correlation with stage of disease

The presence of circulating immune complexes (ICS) in freshly drawn sera of 67 children with neuroblastoma was studied by the Raji cell radioimmunoassay of Theofilopoulos et al. (J. Clin. Invest. 57: 169--182), with particular emphasis on the correlation of levels of ICS with stage of disease and changes attributable to treatment. There was a close correlation between amount of complexes and stage of disease and treatment. Levels of ICS increased as the stage of the disease advanced, and were significantly higher (P less than 0.005) in stage IV than in all other stages combined. When patients with stage IV disease were subdivided into "before," "during," and "after" treatment groups, there was a significant decrease in ICS levels as treatment progressed. Studies of complement and complement components did not give such a clear relationship. A significant decrease of hemolytic C1 values was found in patients with "active disease" compared to normal age-matched controls. Some high C3 levels, determined immunochemically, were associated with low hemolytic levels of C3, which were attributed to C3 cleavage detected by immunoelectrophoresis. Based on our survival data, ICS, which were significantly different in 20 patients now decreased when compared to those of other patients, are very valuable in the prognosis of neuroblastoma.

Composite replacement of the aortic valve and ascending aorta

This report comprises 16 consecutive patients with ascending aortic aneurysms caused by cystic medical necrosis. We replaced the ascending aorta and aortic valve with a tightly woven Dacron graft containing a Lillehei-Kaster valve prosthesis and implanted the coronary ostia in the sides of the graft. All but two patients had massive aortic insufficiency. Postoperative catheterization was performed in 13 patients, and all surviving patients have been seen within the past 6 months. There was one perioperative death (6 percent) and two late deaths. Eleven survivors are in Class I and two are in Class II (N.Y.H.A.). Angiographically demonstrated late complications have included psuedoaneurysms of the coronary ostium (two), paravalvular leak (one), and pseudoaneurysm of the distal suture line (one). Two of these four patients were asymptomatic. Two of the four patients have had successful repair of these defects and a third is awaiting operation. Compositive replacement carries a low operative risk and minimizes problems of intraoperative bleeding. In view of the incidence of late suture line problems, routine angiography 6 to 12 months postoperatively is recommended. If new symptoms occur or if there is a change in the cardiac silhousette on chest roentgenogram, the patient should be recatheterized.

Hemodynamic evaluation of Lillehei-Kaiser and Starr-Edwards prosthesis

The central-flow low profile disc-valve prosthesis has been offered as an alternative to ball- and tissue-valve prostheses. Extensive laboratory investigation with both pulse duplicator and experimental animals has been reported for the Lillehei-Kaster prosthesis. A series of patients receiving this prosthesis underwent postoperative cardiac catheterization to better define the hemodynamic function of this prosthesis in vivo. Because of the variations in reports of hemodynamic data from various institutions, the results of post-operative studies in an earlier group of patients with Starr-Edwards prostheses were used as a standard for comparison. Good hemodynamic function was found with the pivoting-disc prosthesis in all but the smallest valve sizes. Lillehei-Kaster and early model Starr-Edwards prostheses with equivalent tissue annulus dimensions were found to have nearly equal valve areas in vivo in the aortic position. The Lillehei-Kaster mitral valves provided larger areas than Starr-Edwards prostheses in large tissue annulus sizes.

The rate-pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris

In order to evaluate hemodynamic predictors of myocardial oxygen consumption (MVO2), 27 normotensive men with angina pectoris were studied at rest and during a steady state at sympton-tolerated maximal exercise (STME). Myocardial blood flow (MBF) was measured by the nitrous oxide method using gas chromatography. MBF increased by 71% from a resting value of 57.4 +/- 10.2 to 98.3 +/- 15.6 ml/100 g LV/min (P less than 0.001) during STME while MVO2 increased by 81% from a resting value of 6.7 +/- 1.3 to 12.1 +/- 2.8 ml O2/100 g LV/min (P less than 0.001). MVO2 correlated well with heart rate (HR) (r = 0.79), with HR x blood pressure (BP) (r = 0.83), and, adding end-diastolic pressure and peak LV dp/dt as independent variables, slightly improved this correlation (r = .86). Including the ejection period (tension-time index) did not improve the correlation (r = 0.80). Thus, HR and HR x BP, both easily measured hemodynamic variables, are good predictors of MVO2 during exercise in normotensive patients with ischemic heart disease. Including variables reflecting the contractile state of the heart and ventricular volume may further improve the predictability.